163619-04-3

Basic information

• Product Name: Fmoc-D-Trp(Boc)-OH
• Synonyms: N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-N-IN-TERT-BUTYL-OXYCARBONYL-D-TRYPTOPHAN;N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-N-IN-T-BUTYLOXYCARBONYL-D-TRYPTOPHAN;N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-N-IN-T-BUTOXYCARBONYL-D-TRYPTOPHAN;N-ALPHA-9-FLUORENYLMETHOXYCARBONYL-NIN-T-BUTYLOXYCARBONYL-D-TRYPTOPHAN;N-ALPHA-FMOC-N-IN-TERT-BOC-D-TRYPTOPHAN;Fmoc-D-Trp(Boc)-OH >=95.0% (HPLC);N-alpha-(((9H-fluoren-9-yl)methoxy)carbonyl)-1-(tert-butoxycarbonyl)-D-tryptophan;1-[(1,1-Dimethylethoxy)carbonyl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-tryptophan
• CAS NO: 163619-04-3
• Molecular Formula: C31H30N2O6
• Molecular Weight: 526.58
• Product Categories: Amino Acids;Tryptophan [Trp, W];Fmoc-Amino Acids and Derivatives;Fmoc-Amino acid series
• Mol File: 163619-04-3.mol

Chemical Properties

• Appearance: /
• Density: 1.289 g/cm³
• Refractive Index: 1.632
• Storage Temp.: 2-8°C
• PKA: 3.71±0.10(Predicted)
• BRN: 7062970
• CAS DataBase Reference: Fmoc-D-Trp(Boc)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-D-Trp(Boc)-OH(163619-04-3)
• EPA Substance Registry System: Fmoc-D-Trp(Boc)-OH(163619-04-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 163619-04-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Fmoc-D-Trp(Boc)-OH is used as a building block for the synthesis of peptides and proteins due to its unique structure and reactivity. It plays a crucial role in the development of new drugs and therapeutic agents, as well as in the study of protein structure and function.
Used in Research and Development:
In the field of research and development, Fmoc-D-Trp(Boc)-OH is used as a key component in the synthesis of various peptide-based compounds for scientific studies. Its incorporation into peptide sequences allows researchers to investigate the properties and interactions of these molecules, leading to a better understanding of biological processes and the development of novel therapeutic strategies.
Used in Chemical Synthesis:
Fmoc-D-Trp(Boc)-OH is also utilized in chemical synthesis as a protected amino acid derivative. Its protected structure facilitates the selective incorporation of D-tryptophan into peptide chains during solid-phase peptide synthesis, ensuring the desired peptide sequence is obtained with minimal side reactions or racemization.
Overall, Fmoc-D-Trp(Boc)-OH is a versatile and essential compound in the fields of pharmaceuticals, research, and chemical synthesis, contributing to the development of new drugs, therapeutic agents, and a deeper understanding of peptide and protein chemistry.

InChI:InChI=1/C31H30N2O6/c1-31(2,3)39-30(37)33-17-19(20-10-8-9-15-27(20)33)16-26(28(34)35)32-29(36)38-18-25-23-13-6-4-11-21(23)22-12-5-7-14-24(22)25/h4-15,17,25-26H,16,18H2,1-3H3,(H,32,36)(H,34,35)/t26-/m1/s1

Upstream product

• 83451-16-5 (S)-tert-butyl 2-(hydroxyamino)propanoate 
• 1019691-72-5 C₃₇H₃₇N₃O₅S 
• 1604-49-5 methyl (2S)-3-(1H-indol-3-yl)-2-(trifluoroacetamido)propanoate 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 146645-63-8 (2S)-2-amino-3-(1-tert-butoxycarbonylindol-3-yl)propanoic acid 
• 2717-76-2 (S)-N-benzyloxycarbonyl-L-tryptophan methyl ester 
• 643751-42-2 N-carbobenzyloxy-1-tert-butoxycarbonyl-L-tryptophan methyl ester 
• 96238-70-9 1-tert-butoxycarbonyl-L-tryptophane methyl ester 
• 73-22-3 L-Tryptophan 
• 4299-70-1 L-tryptophan methyl ester 

Downstream Products

• 157610-37-2 H-Ala-Ala-D-Trp-Phe-D-Pro-Pro-Nle-NH₂ 
• 396091-74-0 H-Phe-(2S,4R)-(4-OCO-NH-CH₂-CH₂-NH-Boc)-Pro-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-OH 

Relevant articles and documents

COMPOUND FOR PREPARATION OF ANTIBODY-PAYLOAD CONJUGATE AND USE THEREOF

The present application relates to a novel linker for use in bioconjugation, comprising two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which a compound, a peptide, and/or a protein can be directly and/or indirectly linked by a substitution reaction to a desired target molecule, that is, a target molecule.

Method for preparing pharmaceutical intermediate of tryptophan derivative

The synthesis method comprises the following steps: L - tryptophan derivatives are taken as starting materials, and esterification is carried out in sequence. The amidation, Boc protection, hydrolysis, amidation or sequential esterification, amidation, Boc protection, hydrogenation, hydrolysis, amidation yields a target product, a tryptophan derivative pharmaceutical intermediate. The preparation method has the advantages of cheap and easily available raw materials, environment friendliness, less process three wastes, accords with the idea of green pharmacy, mild reaction conditions, simple process, simple and convenient operation, high yield and purity and easy amplification and production.

DIPHENYLMETHANE COMPOUND

Compounds having a diphenylmethane skeleton are superior in broad utility and stability, and are useful as a protecting reagent (anchor) of amino acid and/or peptide in the liquid phase synthesis and the like of a peptide having a C-terminal etc., which are of a carboxamide(-CONHR)-type, and in organic synthetic reaction methods (particularly peptide liquid phase synthetic methods), and may be contained in a kit for peptide liquid phase synthesis.

Stereoretentive synthesis and chemoselective amide-forming ligations of C-terminal peptide α-ketoacids

C-Terminal peptide cyanosulfur ylides are readily converted to C-terminal peptide α-ketoacids, poised for chemoselective amide-forming reactions with hydroxylamines. These easily prepared and bench stable ylides are quickly and selectively oxidized with a

Controlled drug delivery system using the conjugation of drug to biodegradable polyester

The present invention relates to the molecular sustained controlled release system constructed by the conjugation of molecules to be released with biodegradable polyester polymer via covalent bond and method for preparation thereof. In accordance with the present invention, the system may be formulated into microspheres, nanoparticles, or films. The molecular release rate from the above system can be regulated to be proportional to the chemical degradation rate of the biodegradable polyester polymers, resulting in near zero order kinetics profile of release without showing a burst effect. Moreover, the high loading efficiency of hydrophilic drugs can be achieved.

GLP-2 compounds, formulations, and uses thereof

The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.